Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 3 7Phase 1 6Phase 1/2 4Phase NA 1Phase 2/3 1

Status

Recruiting 3Active not recruiting 3Completed 1

Sponsor Class

INDUSTRY 7

Study Type

Interventional 7

Sponsor

Cancer Type

Gastrointestinal 7

Conditions

Carcinoma, Non-Small-Cell Lung 31Lung Neoplasms 9Small Cell Lung Carcinoma 7Biliary Tract Neoplasms 7Carcinoma, Hepatocellular 6Urinary Bladder Neoplasms 4Liver Neoplasms 4Carcinoma 4Neoplasm Metastasis 3Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma Extensive Disease 2Recurrence 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Non-Muscle Invasive Bladder Neoplasms 2Gallbladder Neoplasms 2Endometrial Neoplasms 2Carcinoma, Renal Cell 2Urothelial Cancer 1Sarcoma 1Radiation Pneumonitis 1Pancoast Syndrome 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Non Small Cell Lung Carcinoma NSCLC 1Non Small Cell Lung Cancer NSCLC 1Non - Small Cell Lung Cancer NSCLC 1Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1

Interventions

Gemcitabine 13Cisplatin 11durvalumab 7Oxaliplatin 5Capecitabine 5Fluorouracil 4S 1 (combination) 3Leucovorin 3Irinotecan 3zanidatamab 2gemcitabine-oxaliplatin regimen 2Trastuzumab 2trastuzumab deruxtecan 1pembrolizumab 1niraparib 1neratinib 1ivosidenib 1futibatinib 1envafolimab 1encorafenib 1binimetinib 1becatecarin 1Tegafur 1Pancreaticojejunostomy 1NUC-1031 1Folfox protocol 1Drug Therapy 1Chemotherapy, Adjuvant 1Carboplatin 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 3 × Biliary Tract Neoplasms × durvalumab × Clear all
NCT03875235 2026-05-26

TOPAZ-1

AstraZeneca

Phase 3 Active not recruiting
810 enrolled 24 charts 1 FDA
Gastrointestinal

Biliary Tract Neoplasms

NCT06467357 2026-05-14

DESTINY-BTC01

AstraZeneca

Phase 3 Recruiting
620 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT06282575 2026-05-11

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Jazz Pharmaceuticals

Phase 3 Recruiting
286 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT05771480 2026-04-21

TOURMALINE

AstraZeneca

Phase 3 Active not recruiting
142 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT07221253 2026-03-17

AB02

AstraZeneca

Phase 3 Recruiting
1,100 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence

NCT06591520 2026-01-21

AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer

Akeso

Phase 3 Active not recruiting
682 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT05924880 2025-04-22

TopDouble

AstraZeneca

Phase 3 Completed
116 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡